Guggenheim Remains a Buy on Unicycive Therapeutics (UNCY)
I'm LongbridgeAI, I can summarize articles.Guggenheim analyst Vamil Divan maintained a Buy rating on Unicycive Therapeutics (UNCY) with a $37 price target, despite shares closing at $4.69. B. Riley Securities also issued a Buy rating with a $22 target. UNCY holds a Strong Buy consensus among analysts, with an average price target of $40.33, implying significant upside potential.
In a report released yesterday, Vamil Divan from Guggenheim maintained a Buy rating on Unicycive Therapeutics, with a price target of $37.00. The company’s shares closed yesterday at $4.69.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Divan covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Merck & Company, and Pfizer. According to TipRanks, Divan has an average return of 14.0% and a 58.54% success rate on recommended stocks.
Unicycive Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $40.33, representing a 759.91% upside. In a report released yesterday, B. Riley Securities also maintained a Buy rating on the stock with a $22.00 price target.